Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Harmonizing Maternal and Infant Biospecimen Collection and Processing for Research.

Biopreservation and biobanking·2026

Same author

Pharmacometric modeling of opioid disposition in pregnancy: a systematic review of PopPK and PBPK approaches, model limitations, and future directions.

Frontiers in pharmacology·2026

Same author

Optimization and Characterization of SHIP1 Ligands for Cellular Target Engagement and Activity in Alzheimer's Disease Models.

Journal of medicinal chemistry·2026

Same author

Association of Cannabis use and Survival in patients with heart failure: A claims-based cohort study of commercially insured adults.

American heart journal plus : cardiology research and practice·2026

Same author

Power Profiles of an Extended Depth of Focus Contact Lens for Myopia Management.

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2026

Same author

Outcomes in the treatment of inner ear decompression sickness with hyperbaric oxygen therapy, a systematic review.

Diving and hyperbaric medicine·2026

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Interaction between midazolam and clarithromycin in the elderly.

Sara K Quinney¹, Barbara D Haehner, Melissa B Rhoades

¹Division of Clinical Pharmacology, Indiana University School of Medicine, Wishard Memorial Hospital, W7123 Myers Building, Indianapolis, IN 46202-2879, USA.

British Journal of Clinical Pharmacology

|July 20, 2007

Summary

Clarithromycin significantly reduces midazolam clearance in the elderly by inhibiting both intestinal and hepatic CYP3A. This drug interaction increases midazolam exposure, highlighting the importance of considering these effects in older populations.

Related Experiment Videos

Last Updated: Jul 13, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Area of Science:

Pharmacokinetics
Drug Interactions
Geriatric Medicine

Background:

The elderly population often exhibits altered drug metabolism and clearance.
Cytochrome P450 3A (CYP3A) enzymes play a crucial role in the metabolism of many drugs, including midazolam.
Understanding drug interactions involving CYP3A is vital for safe medication use in older adults.

Purpose of the Study:

To evaluate the contribution of intestinal and hepatic CYP3A inhibition to the interaction between midazolam and clarithromycin in elderly individuals.
To quantify the impact of clarithromycin on midazolam pharmacokinetics in this demographic.

Main Methods:

A pharmacokinetic study involving 16 elderly volunteers (65-75 years).
Administration of intravenous and oral midazolam before and after a 7-day course of oral clarithromycin.
Assay of midazolam and its metabolites in serum and urine using gas chromatography/mass spectrometry.

Main Results:

Clarithromycin significantly decreased systemic and oral midazolam clearance.
Both hepatic and intestinal availability of midazolam were significantly increased after clarithromycin administration.
Clarithromycin increased the area under the curve (AUC) of midazolam by 3.2-fold (i.v.) and 8.0-fold (p.o.).

Conclusions:

Intestinal and hepatic CYP3A inhibition by clarithromycin substantially reduces midazolam clearance in the elderly.
The interaction leads to significantly increased midazolam exposure in older adults.
These findings underscore the clinical relevance of CYP3A-mediated drug interactions in geriatric pharmacotherapy.